Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20%

A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas

(2016) Laura H. Tang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

(2016) R. Garcia-Carbonero et al.   NEUROENDOCRINOLOGY

Small Cell Carcinomas of the Bladder Highly Express Somatostatin Receptor Type 2A

(2016) Nalan Neşe et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms

(2015) Olca Basturk et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas

(2015) L. H. Tang et al.   CLINICAL CANCER RESEARCH

Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role

(2015) George Kanakis et al.   NEUROENDOCRINOLOGY

Pathology, genetics and precursors of human and experimental pancreatic neoplasms: An update

(2015) Irene Esposito et al.   PANCREATOLOGY

Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms

(2015) Daniel Kaemmerer et al.   Oncotarget

Gastroenteropancreatic high-grade neuroendocrine carcinoma

(2014) Halfdan Sorbye et al.   CANCER

Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies

(2014) Michelle D Reid et al.   MODERN PATHOLOGY

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pancreatic neuroendocrine tumors: Pathologic and molecular characteristics

(2014) Chanjuan Shi et al.   SEMINARS IN DIAGNOSTIC PATHOLOGY

Are G3 ENETS neuroendocrine neoplasms heterogeneous?

(2013) Fritz-Line Vélayoudom-Céphise et al.   ENDOCRINE-RELATED CANCER

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry

(2012) Gou Mizutani et al.   ACTA HISTOCHEMICA ET CYTOCHEMICA

Somatostatin Receptor Subtype 2A Immunohistochemistry Using a New Monoclonal Antibody Selects Tumors Suitable for In Vivo Somatostatin Receptor Targeting

(2012) Meike Körner et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors

(2012) Shinichi Yachida et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

(2012) H. Sorbye et al.   ANNALS OF ONCOLOGY

Neuroendocrine tumor disease: an evolving landscape

(2012) Andrea Frilling et al.   ENDOCRINE-RELATED CANCER

Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms

(2011) Günter Klöppel   ENDOCRINE-RELATED CANCER

Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours

(2011) Daniel Kaemmerer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

(2011) Y. Jiao et al.   SCIENCE

Profiling of Somatostatin Receptor Subtype Expression by Quantitative PCR and Correlation With Clinicopathological Features in Pancreatic Endocrine Tumors

(2010) Yoshihito Nakayama et al.   PANCREAS

Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases

(2009) L. Righi et al.   ANNALS OF ONCOLOGY

Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours

(2009) V. Zamora et al.   DIGESTIVE AND LIVER DISEASE

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Peptide-receptor radionuclide therapy for endocrine tumors

(2009) Martijn van Essen et al.   Nature Reviews Endocrinology

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT

(2008) Matthias Miederer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY